Objective: Dijkstra et al recently described a risk-and symptombased score moderately predictive for HIV seroconversion in the preceding 6-12 months in men who have sex with men (MSM) in Amsterdam. Our objective was to determine whether this "Amsterdam Score" could also predict for acute HIV infection (AHI) in MSM. Methods: The Amsterdam Score was calculated for each participant in the study sample. Score performance was assessed using receiver operating characteristic curves and their area under the curve (AUC). An optimal cutoff was determined using the Youden index.
INTRODUCTION
Diagnosis and treatment of acute HIV infection (AHI) has important implications for patient care and public health. HIV nucleic acid testing (NAT) is the most reliable method of detecting AHI, 1 although its routine use is costly. There are identifiable risk factors associated with AHI, 2 and risk behavior-based scores such as the San Diego Early Test score 3 can be used to target resources among men who have sex with men (MSM). Risk behavior-based scores, however, may not generalize well to populations that have different demographics than the derivation population. 4 The addition of symptoms to these scores could enhance their discriminative ability and/or generalizability, as symptoms reflect the acute retroviral syndrome.
Dijkstra et al 5 recently described a risk-and symptombased score (Amsterdam Score) that was moderately predictive for seroconversion in the 6-to 12-month period preceding follow-up in MSM. Their validation cohort comprised MSM in select US cities (not including San Diego). It was proposed that the Amsterdam Score may be cost-saving by reducing HIV NAT utilization while increasing diagnostic yield. In this study, we validated the Amsterdam Score in a cohort composed of MSM presenting for voluntary community-based HIV testing in San Diego who were either HIV-uninfected or diagnosed with AHI.
METHODS

Study Population/Data Collection
This was a case-control analysis of a cohort study and comprised (1) individuals who tested positive for AHI [defined as HIV antibody (Ab)-negative and HIV NATpositive] from 2007 to 2017 through the Early Test program and (2) testing encounters that resulted in a negative HIV NAT from January to July 2017, also through the Early Test program. The Early Test is a free and voluntary communitybased screening program in San Diego, California, in which participants are prospectively enrolled to receive universal point-of-care rapid HIV antibody (Ab) testing, followed by reflex HIV NAT in those who test Ab-negative; blood samples for NAT are obtained at the time of Ab testing. Participants were interviewed regarding risk behaviors for the preceding 3-month period at the time of testing, and symptoms were assessed through questionnaire for the 14 days before testing as described in previous works. 3,6-9 HIVnegative participants and AHI participants were included from differing periods because symptoms were not systematically and universally assessed before 2017.
Amsterdam Score and Adjustments
The Amsterdam Score was calculated for each participant using point values described in Dijkstra et al 5 (Table 1) . Symptoms and risk behaviors were both assessed for the 6 months before testing in the derivation and validation cohorts used in the original work. To take into account the 3-month risk reporting period in the Early Test, we created an "adjusted Amsterdam Score" by adjusting 1 original variable ".5 sexual partners in the previous 6 months" to ".3 sexual partners in the previous 3 months," retaining the same point value. 5 Participant-reported oral thrush was not assessed in the San Diego cohort.
Statistical Analysis
Statistical analysis was performed using R version 3.1.1 and package "pROC." 10,11 The 2-tailed significance level was P , 0.05.
Values that were "missing" (collected in the San Diego cohort but were not reported by certain participants) were handled using 3 methods: (1) retention of unreported variables with their values coded as "0" (meaning "negative" or "absent") to produce a more conservative analysis, (2) listwise deletion of cases with any missing variables, and (3) multiple imputation with chained equations using 5 iterations and 5 imputations.
Risk behavior prevalence was compared between the original validation cohort [the Multicenter Aids Cohort Study (MACS) 5 ] and the San Diego cohort using Pearson x 2 statistics. MACS data were supplied by Dijkstra et al.
Performance of the Amsterdam Score was assessed using receiver operating characteristic (ROC) curves and areas under the curve (AUCs) with 95% confidence intervals (95% CIs). Four ROC curves were generated, between the Amsterdam Score, the adjusted Amsterdam Score, and the 2 strategies for nonreported variables. Optimal cutoff scores were determined using the Youden index. As a sensitivity analysis, AUCs were compared using the DeLong method. 12 The hypothesis of this study was that the Amsterdam Score would be at least moderately predictive for AHI in the San Diego cohort (ROC AUC .= 0.70). We found that ROC AUCs did not differ significantly by adjusted/unadjusted Amsterdam Scores, nor by missing data methods. Therefore, for clarity, we only discuss in detail results using the 
RESULTS
Demographics
Seven hundred fifty-seven MSM cases (110 AHI and 647 HIV NAT-negative) were included in the analysis. The 647 HIV-negative cases represented 591 unique individuals. AHI and HIV-negative cases did not differ significantly in age [median 32 years (interquartile range 26-42) vs 33 (interquartile range 27-45), respectively, P = 0.082], Hispanic ethnicity (33.6% vs 31.8%, P = 0.71), and white race (69.7% vs 63.7%, P = 0.22).
Symptom/Risk Variables
Proportions of participants among AHI and HIVnegative cases who met the definition of each Amsterdam Score variable, as well as the proportion of missing variables, are shown in Table 1 . Compared with the MACS cohort, the San Diego cohort had significantly greater prevalence of gonorrhea (3.2% vs 0.4%, P , 0.001) and condomless receptive anal intercourse (51.8% vs 23.9%, P , 0.001), while the proportion who reported having .5 sexual partners was similar (24.3% vs 26.6%, P = 0.17).
Amsterdam Score Performance
The unadjusted Amsterdam Score yielded a ROC AUC of 0.878 (95% CI 0.844 to 0.913) when applied to the sample with missing variables retained. Sensitivity analyses using the adjusted/unadjusted Amsterdam Scores and 2 missing datahandling methods produced ROC curves with a range of AUCs from 0.877 to 0.896; these ROC curves are shown in Figure 1 , Supplemental Digital Content, http://links.lww.com/ QAI/B195. Table 2 shows the sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio at each unadjusted Amsterdam Score cutoff when applied to the sample in which missing variables were retained. The optimal cutoff was $1.6, yielding a sensitivity of 78.2%, specificity of 81.0%, positive likelihood ratio (+LR) of 4.11, and negative likelihood ratio (2LR) of 0.24 for AHI. At a cutoff of $1.6 (eg, fever or gonorrhea or any combination of 2 variables), 23/110 AHI cases would have been missed, whereas 123/647 participants without HIV infection would have received NAT. At a cutoff of $0.9 (eg, any 1 variable), 108/110 AHI cases would have been submitted for NAT testing, whereas 392/647 participants without HIV would have received NAT. Sensitivity analyses of optimal cutoffs and diagnostic parameters at these cutoffs are shown in Table   1 , Supplemental Digital Content, http://links.lww.com/QAI/ B195.
DISCUSSION
The risk-and symptom-based Amsterdam Score was predictive for AHI when applied to a San Diego-based cohort of MSM undergoing voluntary, community-based HIV screening who tested Ab-negative. Even when using a shorter risk-behavior reporting period in this cohort and a conservative approach to missing data, the AUC of 0.878 found in this study exceeded the AUC described by Dijkstra et al (0.78, 95% CI: 0.74 to 0.82) in their US based validation cohort (the MACS). 5 The better performance in the San Diego MSM cohort is likely explained by our "AHI-positive" case and "HIV-negative" control definitions based on routine HIV NAT testing, compared with definitions used in the derivation and validation cohorts in Dijkstra et al. In that work, positives were defined by a new positive HIV-1 antibody test followed by confirmatory Western blot, while HIV-negative cases were defined by a negative HIV-1 antibody test. 5 The Amsterdam Score was also expected to perform better in the San Diego cohort because symptoms were assessed for the previous 14 days (vs 6 months in the MACS).
The optimal cutoff for the Amsterdam Score in our cohort was only slightly higher than that in the original validation cohort ($1.6 points), 5 despite our omission of the "oral thrush" variable. This may reflect either the greater prevalence of risk behaviors in the San Diego cohort, or that oral thrush was reported only in 2.3% of the original Amsterdam derivation sample. At our respective optimal cutoffs, we found a much higher sensitivity (78.2% vs 56.2%, P , 0.001) and relatively small decrease in specificity (81.0% vs 88.8%, P , 0.001) compared with when the Amsterdam Score was applied to the MACS cohort. If the purpose of the Amsterdam Score is to reduce NAT utilization among those who test Ab-negative, the trade-off of potentially missing AHI diagnoses must be balanced with the cost-savings of avoiding unnecessary NAT tests in those who are ultimately HIV-negative. In our sample, a more clinically appropriate cutoff may be $0.9, which had over 98% sensitivity, but would still help to spare more than 35% of NAT tests among those who first test Ab-negative. The risk of a false-positive HIV NAT after a negative HIV-Ab test is minimal and would be of even lesser consequence when followed by a confirmatory western blot. Similarly, the risk of a false-negative HIV NAT is small to minimal. 13 We showed that the performance of the Amsterdam Score was maintained and stable even when using different reporting periods for risk behaviors (3 months in this cohort vs 6 months in Dijkstra et al 5 ) and for symptoms (14 days in this cohort vs 6 months in Dijkstra et al). Similar AUCs in adjusted and nonadjusted analyses may also indicate that the original, unadjusted Amsterdam Score could be used in different settings that assess risk behaviors over 3 months, without significant loss of predictive power. Using a 3-month risk assessment period may be advantageous, as i) participant recollection may be more accurate, and ii) it can exclude those who engaged in risk behaviors in the previous 4-6 months but not in the 3 months before testing. Similarly, a symptom-reporting period of 14 days (compared to 6 months) likely improved specificity for AHI by reducing noise associated with more common causes of fever, such as a upper respiratory infection. All in all, we would recommend using the adjusted Amsterdam Score for its shorter reporting periods and because it is simpler with the exclusion of oral thrush. Validation of the adjusted Amsterdam Score in other cohorts and other periods of assessment would lend further support to its use in different settings. Although scores that incorporate symptoms may be more generalizable in theory, symptoms still have the potential to underpredict for AHI, especially in regions with different HIV-1 subtype epidemics. 14 There are important limitations to note, including missing data and differing assessment periods between cohorts, which we aimed to address with sensitivity analyses. An additional limitation of this analysis was that the HIVnegative cases and AHI cases were recruited across different periods. This was because symptoms among HIV-negative cases were only collected starting in 2017. This has the potential to bias our results if patterns in the reporting of behaviors or symptoms differed across time. A subanalysis of MSM recruited during the same period was not possible because only 2 participants were diagnosed with AHI in 2017. Finally, our validation sample did not include participants who tested Ab-positive. Therefore, our findings were limited only to validating the use of the Amsterdam Score in MSM who initially test Ab-negative.
CONCLUSIONS
The Amsterdam Score was predictive of AHI in MSM in San Diego, despite a shorter risk-behavior assessment period and a conservative analysis of missing variables. The improved performance is likely attributable to our definition of positive cases as Ab-negative, NAT-positive AHI, compared with seroconversion in the preceding 6-to 12-month period in the original work. Combined risk-and symptombased scores may demonstrate improved generalizability across different populations compared with existing riskbased scores, 3 and when applied to MSM who test Abnegative, may increase the yield of AHI detection while reducing testing costs in settings that do not routinely test for AHI.
